There are a lot of options for investors on the ASX 200 index.
To narrow things down, let's take a look at what Morgans is saying about three popular ASX 200 shares.
Does it rate them as buys, holds, or sells? Let's find out:
Image source: Getty Images
Collins Foods Ltd (ASX: CKF)
Morgans is feeling positive about this KFC-focused quick service restaurant operator ahead of its upcoming results.
While it has trimmed its estimates to reflect a number of items, this is partially offset by a stronger than expected performance in the Australian market.
As a result, it has retained its buy rating with a slightly reduced price target of $12.50. It said:
We revise our CKF forecasts ahead of the FY26 result in June, trimming underlying NPAT to reflect deferred store openings, reset German acquired store economics, and a lower EU SSS assumption to better capture the Netherlands-skewed mix for FY26, partially offset by a marginal AU SSS upgrade on sustained KFC Australia momentum. We maintain our BUY recommendation and reduce our price target to $12.50 (from $12.70).
Netwealth Group Ltd (ASX: NWL)
This investment platform provider delivered a third-quarter update that was slightly ahead of expectations.
And with the new quarter starting strongly for financial markets, Morgans appears to believe it could build on this.
This has seen the broker put an accumulate rating and $29.00 price target on Netwealth's shares. It commented:
NWL's 3Q26 net-flows of $3.96bn came in modestly ahead of expectations, however market volatility during the period eroded this solid performance to see 3Q26 FUA ending the quarter flat QoQ at A$125.8bn, (vs. Consensus A$129.8bn). Despite ongoing volatility and uncertainty tied to a US/Middle East conflict and a potential resolution, market momentum has recovered from peak pessimism in the March Quarter, with the ASX All Ordinaries +5.6% month-to-date in April'26, which will have seen FUA growth momentum improve post quarter end.
Looking through this near-term volatility NWL remains on track deliver solid growth FY26F and well placed to capitalised on the long runway of opportunity ahead. We retain our ACCUMULATE rating, with a Price target of $29.00/sh.
Pro Medicus Ltd (ASX: PME)
Finally, after adjusting its model for Pro Medicus to reflect more achievable growth estimates, the broker continues to see a lot of value in its shares.
The broker has retained its buy rating on Pro Medicus shares with a reduced price target of $210.00. It commented:
In this note, we deploy a new PME model where we have deliberately set a lower bar. Our remodelled estimates prioritise achievability over optimism, staging implementation revenue conservatively and mark FX to spot. We see this as the right framework for a stock where sentiment has been fragile.
On the business operations front, the story remains untarnished. Contract newsflow since February has been exceptional: ~$100m in wins and renewals, all at higher pricing, with cardiology upsell gaining traction. The demand story is not in question. We re-emphasise our positive long-term conviction on the name although lower our valuation to reflect current but potentially fleeting headwinds. Our target price is reduced to A$210 p/s and we retain our Buy recommendation.
